Jam

Faraday Future’s Global President, Jerry Wang, will present at the Global Capital Network Investor Conference on June 19, 2025, in Newport Beach. He will deliver a keynote, participate in an investor Q&A, and discuss the company’s AI-driven mobility solutions and 2025 initiatives. The company will also showcase the FF 91 2.0 and offer test rides at their booth.

SBC Medical Group showcased its expertise at the 113th Congress of Japan Society of Aesthetic Surgery, with 22 representatives from Shonan Beauty Clinic. CEO Yoshiyuki Aikawa and other experts presented research findings and participated in discussions on global trends in aesthetic medicine. This event highlighted SBC Medical’s commitment to innovation and its presence in a growing market.

Banco Macro S.A. announced the pricing of $400 million in Notes due 2029, yielding 8.000% annually. The fixed-rate notes, part of a larger financing program, mature on June 23, 2029, and were priced at 99.163%. Proceeds will fund strategic initiatives, including refinancing debt, capital expenditures, and acquisitions within Argentina, as part of a $1.5 billion debt securities issuance strategy. The Notes were not registered under U.S. securities laws.

Ira Subaru of Danvers, MA, is donating $41,038 and employee volunteer time to Essex County Habitat for Humanity. This initiative supports the organization’s mission of providing safe and affordable housing. The contribution, part of Group 1 Automotive’s community commitment, includes a check presentation and volunteer work for a home-building project. The event will take place on June 18, 2025, at 436 Asbury St., Hamilton, MA.

Kite Realty Group Trust (KRG) announced a $300 million senior notes offering by Kite Realty Group, L.P., consisting of 5.200% Senior Notes due 2032. The notes are offered at 99.513% of face value, yielding 5.281% to maturity, with semi-annual interest payments. Proceeds will be used to repay debt and for general corporate purposes. Closing is expected on June 27, 2025. KRG, a REIT focused on grocery-anchored properties, owns 180 shopping centers.

Eyenovia, Inc. is pivoting into the digital asset space with a $50 million private placement to acquire over 1,000,000 HYPE tokens from Hyperliquid, becoming the first U.S.-based public company to hold a substantial amount. This investment, coupled with the appointment of a Chief Investment Officer, positions Eyenovia as a top-tier validator. Simultaneously, Eyenovia will continue ophthalmic technology development, reflecting a dual strategy to create value, while also launching a HYPE staking program. The company is planning to change its name and ticker.

EIG Asset Management LLC decreased its stake in Diversified Energy PLC (DEC), reducing its total voting rights from 20.21% to 18.20%, a change equivalent to 14,330,718 shares. The transaction, reported on June 17, 2025, occurred on May 27, 2025. EIG’s holdings are distributed through multiple entities, with EIG Energy Fund XVI, L.P. holding the largest individual position. This impacts shareholder influence, based on a total issued share capital of 78,757,014.

VEON Ltd. and Ukraine’s Ministry of Digital Transformation are partnering to create Ukraine’s first large language model (LLM), trained exclusively on Ukrainian data. This project, fueled by VEON’s $1 billion infrastructure investment, aims to develop a secure, culturally relevant AI ecosystem. The LLM will power AI-driven tools tailored to Ukrainian needs, specifically in sectors like government and healthcare. The first version is expected by December 2025, led by Kyivstar, aiming to enhance digital sovereignty and economic growth.

Pinwheel is expanding its solutions on the Jack Henry digital banking platform. This includes the Switch Kit and Bill Navigator, streamlining account activation and bill management for community and regional financial institutions. These features aim to simplify onboarding, allowing customers to easily switch deposits and bills, potentially saving money and enhancing customer loyalty.

Eli Lilly will acquire Verve Therapeutics, a clinical-stage company focused on gene editing therapies for cardiovascular disease. The deal, valued at approximately $1 billion, aims to advance Verve’s one-time treatment approach targeting genes linked to heart disease. Lilly plans to leverage its expertise in cardiometabolic diseases and gene medicines to develop Verve’s pipeline, including VERVE-102.